drugset / Trial / NCT07067385
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Phase 1
Recruiting
40 enrolled
Ruijin Hospital
Bio-X Institutes, Shanghai Jiao Tong University · collabdeepGeneAI · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors
Timeline
- Start
- 2025-07-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neoantigen Personalized Cancer Vaccine | Messenger RNA (mRNA) | — | — |